PI3K inhibitors in haematological malignancies

Lancet Oncol. 2022 Aug;23(8):e365. doi: 10.1016/S1470-2045(22)00332-1.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Hematologic Neoplasms* / drug therapy
  • Humans
  • Phosphatidylinositol 3-Kinases*
  • Phosphoinositide-3 Kinase Inhibitors / therapeutic use

Substances

  • Phosphoinositide-3 Kinase Inhibitors